Drug intelligence / Profile preview

L-CTM

Development stage: Preclinical
Lead developer: Celularity
Administration: Implant

Overview

L-CTM is a liquid formulation of decellularized placental connective tissue matrix (CTM) developed by Celularity. It is derived from human placental connective tissue and is designed for the management and protection of tendon injuries. As a decellularized biomaterial, L-CTM aims to provide a regenerative scaffold that supports tenocyte functionalities, including adhesion and proliferation, while minimizing immunogenicity and promoting tissue integration. In preclinical studies, L-CTM has been evaluated alongside other placental-derived biomaterials, such as particulate and flowable formats, to assess its biomechanical properties and its ability to support tendon healing and phenotype maintenance in models of tendon insult.

Other names: liquid connective tissue matrixliquid matrix CTM

Beyond the preview

Go deeper on L-CTM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-CTM.

Explore the full profile